NasdaqGM - Nasdaq Real Time Price USD

NeuroPace, Inc. (NPCE)

16.13 -0.34 (-2.06%)
As of 11:34:45 AM EDT. Market Open.
Trade NPCE on Coinbase
Chart Range Bar
Loading chart for NPCE
  • Previous Close 16.47
  • Open 16.12
  • Bid 11.70 x 200
  • Ask 20.67 x 100
  • Day's Range 15.85 - 16.49
  • 52 Week Range 7.56 - 19.60
  • Volume 22,239
  • Avg. Volume 187,183
  • Market Cap (intraday) 549.932M
  • Beta (5Y Monthly) 1.89
  • PE Ratio (TTM) --
  • EPS (TTM) -0.65
  • Earnings Date (est.) Aug 11, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 20.00

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

www.neuropace.com

220

Full Time Employees

December 31

Fiscal Year Ends

Performance Overview

Trailing total returns as of 7/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NPCE
4.47%
S&P 500 (^GSPC)
9.30%

1-Year Return

NPCE
77.64%
S&P 500 (^GSPC)
18.81%

3-Year Return

NPCE
284.96%
S&P 500 (^GSPC)
65.43%

5-Year Return

NPCE
30.74%
S&P 500 (^GSPC)
72.91%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 26.59M
Earnings -2.73M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

0
10M
20M
 

Analyst Insights

View More

Analyst Price Targets

18.00
20.00 Average
16.13 Current
22.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 5/15/2026
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 19 -> 20
 

Statistics

View More

Valuation Measures

Annual
As of 7/16/2026
  • Market Cap

    562.21M

  • Enterprise Value

    578.69M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.51

  • Price/Book (mrq)

    38.90

  • Enterprise Value/Revenue

    5.81

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -21.67%

  • Return on Assets (ttm)

    -10.02%

  • Return on Equity (ttm)

    -111.38%

  • Revenue (ttm)

    99.53M

  • Net Income Avi to Common (ttm)

    -21.57M

  • Diluted EPS (ttm)

    -0.65

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    53.98M

  • Total Debt/Equity (mrq)

    487.49%

  • Levered Free Cash Flow (ttm)

    -2.74M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

16.13 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

People Also Watch